Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 9/2018

Open Access 01-09-2018 | Review

Identifying cisplatin-induced kidney damage in paediatric oncology patients

Authors: Chris D. Barton, Barry Pizer, Caroline Jones, Louise Oni, Munir Pirmohamed, Daniel B. Hawcutt

Published in: Pediatric Nephrology | Issue 9/2018

Login to get access

Abstract

Cisplatin is one chemotherapeutic agent used to treat childhood cancer in numerous treatment protocols, including as a single agent. It is likely to remain in clinical use over the long term. However, cisplatin-related toxicities, including neurotoxicity and nephrotoxicity, are common, affecting treatment, day-to-day life and survival of such children. With one in 700 young adults having survived childhood cancer, patients who have completed chemotherapy that includes cisplatin can experience long-term morbidity due to treatment-related adverse reactions. A better understanding of these toxicities is essential to facilitate prevention, surveillance and management. This review article discusses the effect of cisplatin-induced nephrotoxicity (Cis-N) in children and considers the underlying mechanisms. We focus on clinical features and identification of Cis-N (e.g. investigations and biomarkers) and the importance of magnesium homeostasis and supplementation.
Literature
1.
Campbell J, Wallace WHB, Bhatti LA, Stockton DL, Rapson T, Brewster DH (2004) Childhood Cancer in Scotland: Trends in incidence, mortality and survival. Information & Statistics Division, Edinburgh, pp 1975–1999
2.
3.
4.
Dasari S, Tchounwu PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharm 740:264–278CrossRef
5.
Brozovic A, Abrimovic-Ristov A, Osmak M (2010) The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit Rev Toxicol 40:347–359CrossRefPubMed
6.
7.
Shrivatsa A, Kuzontkoski PM, Groopman JE, Prasad A (2011) Cannabidol induces programmed cell death in breath cancer cells by coordinating the cross between apoptosis and autopehagy. Mol Cancer Ther 10:1161–1172CrossRef
8.
9.
Winograd-Katz SE, Levitzki A (2006) Cisplatin induces PKB/Akt activation and p38 (MAPK) phosphorylation of the RGF receptor. Oncogene 25:7381–7390CrossRefPubMed
10.
Lewis MA, Shaw J, Sinha M, Adalat S, Hussain F, Inward C (2008) Demography of the UK paediatric renal replacement therapy population. In: Ansell D, Feest T, Williams A (eds) UK renal registry report 2008. UK Renal Registry UK, Bristol, pp 257–267
11.
Brock PR, Koliouskas DE, Barratt TM, Yeomans E, Pritchard J (1991) Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118:531–534CrossRefPubMed
12.
Hartmann O, Pinkerton CR, Philip T, Zucker MJ, Breatnach F (1988) Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol 6:44–50CrossRefPubMed
13.
Kulhman MK, Burkhardt G, Kohler H (1997) Insights into potential cellular mechanisms ofcisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12:2478–2480CrossRef
14.
Kroning R, Lichtenstein AK, Nagami GT (2000) Sulfur-containing amino acids decreasecisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol 45:43–49CrossRefPubMed
15.
O’Dwyer PJ, Stevenson JP, Johnson SW (2000) Clinical pharmacokinetics of established platinum drugs. Drugs 59:19–27CrossRefPubMed
16.
Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 99:14298–14302CrossRefPubMedPubMedCentral
17.
Peres LA, da Cuhna AD Jr (2013) Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras Nefrol 35:332–340CrossRefPubMed
18.
19.
20.
Wang Q, Shi S, He W, Padill MT, Zhang L, Wang X, Zhang B, Lin Y (2015) Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition. Oncotarget 5:1304–1314
21.
22.
Filipski KK, Loos WJ, Verweij J, Sparreboom A (2008) Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 14:3875–3880CrossRefPubMed
23.
Choi MK, Song IS (2008) Organic cation transporters and their pharmacokinetic and pharmacodynamics consequences. Drug Metab Pharmacokinet 23:243–253CrossRefPubMed
24.
25.
Rangathan R, Hamad R, Mohamed R, Jayakumar C, Muthusamy T, Ramesh G (2016) Histone deacetylase mediated silencing of AMWAP expression contributes to cisplatin nephrotoxicity. Kidney Int 89:317–326CrossRef
26.
Zhuang S, Tang J (2016) Upregulation of AMWAP: a novel mechanism for HDAC inhibitors to protect against cisplatin nephrotoxicity. Kidney Int 89:267–269CrossRefPubMed
27.
Groh T, Hrabeta J, Khalil MA, Doktorova H, Eckschlager T, Stiborova M (2015) The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells. Int J Oncol 47:343–352CrossRefPubMed
28.
Dong G, Kumar V, Dong Z (2010) Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Am J Physiol Ren Physiol 298:F293–F300CrossRef
29.
Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, Lovelace E, Reid RC, Le GT, Hume DA, Irvine KM, Matthias P, Fairlie DP, Sweet MJ (2010) Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the toll-like receptor 4 agonist LPS. J Leukoc Biol 87:1103–1114CrossRefPubMed
30.
31.
Solanki MH, Chatterjee PK, Gupta M, Xue X, Plagov A, Metz MH, Mintz R, Singhal PC, Metz CN (2014) Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation. Am J Physiol Ren Physiol 307:F369–F384CrossRef
32.
Solanki MH, Chatterjee PK, Xue X, Gupta M, Rosales I, Yeboah MM, Kohn M, Metz CN (2015) Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice. Am J Physiol Ren Physiol 309:F35–F47CrossRef
33.
Mehta RL, Awdishu L, Davenport A, Murray PT, Macedo E, Cerda J, Chakaravarthi R, Holden AL, Goldstein SL (2015) Phenotype standardization for drug induced kindey disease. Kidney Int 88:236–234CrossRef
34.
35.
Erdlenbruch B, Nier M, Kern W, Hiddemen W, Pekrun A, Lakomek M (2001) Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol 57:393–402CrossRefPubMed
36.
Loebstein R, Koren G (1998) Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics 101:e8CrossRefPubMed
37.
Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115–124CrossRefPubMed
38.
39.
Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, Slejfer DT (2000) Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 355:1075–1076CrossRefPubMed
40.
Erdlenbruch B, Pekrun A, Roth C, Grunewald RW, Kern W, Lakomek M (2001) Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions. Pediatr Nephrol 16:586–593CrossRefPubMed
41.
Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD (2009) Persistent nephrotoxicity during ten year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45:3213–3219CrossRefPubMed
42.
Jones DP, Spunt SL, Green D, Springate JE (2008) Renal late effects in patients treated for cancer in childhood: areport from the Children’s oncology group. Pediatr Blood Cancer 51:724–731CrossRefPubMedPubMedCentral
43.
Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ (2015) Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet 47:263–266CrossRefPubMedPubMedCentral
44.
Campbell AB, Kalman SM, Jacobs C (1983) Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rev 67:169–172
45.
Kelsen DP, Alcock N, Young CW (1985) Cisplatin nephrotoxicity correlation with plasma platinum concentrations. Am J Clin Oncol 8:77–80CrossRefPubMed
46.
Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, Ohno T, Masuhara K, Tanaka Y, Kato K, Nagai H, Yokoyama A, Kurita Y (1996) Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 39:131–137CrossRefPubMed
47.
Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin and ormplatin. Gynecol Oncol 50:147–158CrossRefPubMed
48.
Waring WS, Moonie A (2011) Earlier detection of nephrotoxicity using biomarkers of acute injury. Clin Toxicol 49:720–728CrossRef
49.
Cerda J (2011) Oliguria: an early and accurate biomarker of acute kidney injury? Kidney Int 80:699–701CrossRefPubMed
50.
Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A (2007) Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31CrossRefPubMedPubMedCentral
51.
Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL (2007) Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 71:1028–1035CrossRefPubMed
52.
53.
Waiker SS, Bonventre JV (2009) Creatinien kinetics and the definition of acute kidney injury. J Am Soc Nephrol 20:672–679CrossRef
54.
Zareifar, Jafari H, Geramizadeh B, Basiratnia M, Golafshan H, Cohan N, Mehravar Z, Hamidi R (2013) The evaluation of cisplatin effect on tubular function in children. Pediatr Hematol Oncol 31:18–24CrossRef
55.
56.
Arga M, Oguz A, Pinarli FG, Karadeniz C, Citak EC, Emeksiz HC, Duran EA, Soylemezoglu O (2015) Risk Factorsfor cisplatin-induced long-term nephrotoxicity in pediatric cancer survivors. Pediatr Int 57:406–413CrossRefPubMed
57.
Lakshminarayana SP, Rajesh AM, George K, Unni VN (2013) Chronic ifosfamide and cisplatin induced nephrotoxicity in a case of primary pulmonary syniovial sarcoma. Amrita J Med 9:28–31
58.
Singh NP, Ganguli A, Parkash A (2003) Drug induced kidney diseases. J Assoc Physicians India 51:970–979PubMed
59.
Varrier M, Fisher M, Ostermann M (2015) Acute kidney injury – an update. EMJ Nephrol 3:75–82
60.
Zubowska M, Wyka K, Fendler W, Mlynarski W, Zalewska-Szwecyzk B (2013) Interleukin-18 as marker of chronic nephropathy in children after anticancer treatment. Dis Markers 35:811–818CrossRefPubMedPubMedCentral
61.
Blessy G, Wen X, Ellison L, Joy M, Aleksunes L (2015) Urinary KIM-1 is a novel biomarker for cisplatin-induced subclinical nephrotoxicity in oncology patients. FASEB J 29(Suppl 1):938.6
62.
Lin HY, Lee SC, Lin SF, Hisai HH, Liu YC, Yang WC, Hwang DY, Hung CC, Chen HC, Guh JY (2013) Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung J Med Sci 29:304–311CrossRefPubMed
63.
Tekce BK, Uyeturk U, Tekce H, Uyeturk U, Arktas G, Akkaya A (2015) Does the kindney injury molecule-1 predict cisplatin induced kidney injury in early stage? Ann Clin Biochem 52:88–94CrossRefPubMed
64.
Bolke E, Matuschek C, Peiper M, Giro C, Pelzer M, Budach W, Gripp S (2008) Cystatin C – a sensitive diagnostic marker for evaluation of the renal function in patients with cisplatin based chemotherapy. J Clin Oncol 26(15S):13520CrossRef
65.
Ostermann M, Joannidis M (2015) Biomarkers for AKI improve clinical practice: no. Intensive Care Med 41:618–622CrossRefPubMed
66.
Lam M, Adelstein DJ (1986) Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis 8:164–169CrossRefPubMed
67.
Womer RB, Pritchard J, Barratt TM (1985) Renal toxicity of cisplatin in children. J Pediatr 106:659–663CrossRefPubMed
68.
Stohr W, Paulides M, Bielack S, Jurgens H, Koscielniak E, Rossi R, Langer T, Beck JD (2007) Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 48:140–147CrossRefPubMed
69.
Kamalaker P, Freeman AI, Higby DJ, Wallace HJ Jr, Sinks LF (1977) Clinical response and toxicity with cis-dichlorodiammine-platinum (II) in children. Cancer Treat Rep 61:835–839
70.
Wilmes A, Bielow C, Ranninger C, Bellwon P, Aschauer L, Limonciel A, Chassaigne H, Kristl T, Aiche S, Huber CG, Guillou C, Hewitt P, Leonard MO, Dekant W, Bois F, Jennings P (2014) Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol in Vitro 30:117–127CrossRefPubMed
71.
Ledeganck KJ, Boulet GA, Bogers JJ, Verpooten GA, De Winter BY (2013) The TRPM6 pathway is downregulated in a rat model of cisplatin nephrotoxicity. PLoS One 8:e57016CrossRefPubMedPubMedCentral
72.
Gong Y, Renigunta V, Zhou Y, Sunq A, Wang J, Yang J, Renigunta A, Baker LA, Hou J (2015) Biochemical and biophysical analysis of tight junction permeability made of claudin-16 and claudin-19 dimerisation. Mol Biol Cell 26:4333–4336CrossRefPubMedPubMedCentral
73.
Kaplinsky C, Alon US (2014) Magnesium homeostasis and hypomagnesemia in children with malignancy. Pediatr Blood Cancer 60:734–740CrossRef
74.
75.
Gettes LS (1992) Electrolyte abnormalities underlying lethal and ventricular arrhythmias. Circulation 85(1 Suppl 1):170–176
76.
77.
Ariceta G, Rodriguez-Soriano J, Vallo A, Navajas A (1997) Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 28:35–40CrossRefPubMed
78.
Oka T, Kimura T, Suzumura T, Yoshimoto N, Nakai T, Yamamoto N, Matsuura K, Mitsuoka S, Yoshimura N, Kudoh S, Hirata K (2014) Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-basd chemotherapy in patients with lung cancer: a toxicity study. BMC Pharmacol Toxicol 15:70CrossRefPubMedPubMedCentral
79.
Kidera Y, Kawakami H, Sakiyama T, Okamato K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nagakawa K (2014) Risk factors for Cisplatin-induced Nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One 9:e101902CrossRefPubMedPubMedCentral
80.
Pratt CB, Meyer WH, Jenkins JJ, Avery L, McKay CP, Wyatt RJ, Hancock ML (1991) Ifosfamide, Fanconi’s syndrome, and rickets. J Clin Oncol 9:1495–1499CrossRefPubMed
81.
Cortina G, Hansford JR, Duke T (2016) Central diabetes Insipidus and cisplatin-induced renal salt wasting syndrome: a challenging situation. Pediatr Blood Cancer 63:925–927CrossRefPubMed
82.
Hamdi T, Latta S, Jallad B, Kheir F, Alhosaini MN, Patel A (2010) Cisplatin-induced renal salt wasting syndrome. South Med J 103:793–799CrossRefPubMed
83.
Jimenz Triana CA, Castelan-Martinez OD, Rivas-Ruiz R, Jemenz-Mendez R, Medina A, Clark P, Rassekh R, Castaneda-Hernandez G, Carleton B, Medeiros M (2015) Cisplatin nephrotoxicity and longitudinal growth in children with solid tumours. Medicine (Baltimore) 94:e1413CrossRef
84.
Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bökenkamp A, Blufpand H, van Dulmen-den Broeder E, Veening MA, Kremer LC, Jaspers MW (2013) Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 10:CD008944
Metadata
Title
Identifying cisplatin-induced kidney damage in paediatric oncology patients
Authors
Chris D. Barton
Barry Pizer
Caroline Jones
Louise Oni
Munir Pirmohamed
Daniel B. Hawcutt
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 9/2018
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-017-3765-6

Other articles of this Issue 9/2018

Pediatric Nephrology 9/2018 Go to the issue

Review

Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials

Clinical Quiz

Submandibular lymphadenopathy in a child post-renal transplant—“What lies beneath?!”: Questions

Original Article

Combining GFR estimates from cystatin C and creatinine—what is the optimal mix?

Original Article

Incidence, risk factors, and outcome of neonatal acute kidney injury: a prospective cohort study

Original Article

Distal renal tubular acidosis. Clinical manifestations in patients with different underlying gene mutations

Educational Review

Thrombotic microangiopathy following haematopoietic stem cell transplant